Status:
COMPLETED
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Lead Sponsor:
Cartesian Therapeutics
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following in...
Eligibility Criteria
Inclusion
- Patients must be 18 years of age or older at the time of enrollment
- High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).
Exclusion
- Patients who are pregnant or lactating.
- Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.
Key Trial Info
Start Date :
February 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 9 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04436029
Start Date
February 24 2021
End Date
April 9 2022
Last Update
December 3 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
2
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
3
Stephenson Cancer Center Oklahoma University Health Science Centers
Oklahoma City, Oklahoma, United States, 73104
4
Medical College of Wisconsin
Madison, Wisconsin, United States, 53226